Loading…
← CockpitCompetitor Analysis › 300676.SZ BGI Genomics Co. Ltd. Class AOpen in the cockpit ↗

BGI Genomics Co. Ltd. Class A300676.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese genomics company providing DNA sequencing services and equipment, including prenatal genetic testing.

≈ A Chinese Illumina/Natera hybridMomentum neutral 52
Mkt cap
$2.13B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$53.7M
20-day average traded
Fwd P/E
126.7×
forward earnings
ROIC−WACC
-11.0 pp
WACC 9.7%
Hurdle
n/a
no reverse DCF
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥34.80
1D-1.6%
1W-10.7%
1M-17.1%
3M-17.0%
6M-14.6%
YTD-23.3%
1Y-28.4%
ATR %5.2%
52w lowhigh46.5% off high

What BGI Genomics does

Chinese genomics company providing DNA sequencing services and equipment, including prenatal genetic testing.

Earns by running genetic tests in its own labs and billing hospitals, health programs and research buyers per test, with prenatal screening the volume line. It belongs to the BGI group, whose sequencing-machine maker is a separate listed company, so this arm sells results rather than instruments.

In one line: A Chinese Illumina/Natera hybrid.

Products and services

  • Non-invasive prenatal testing (NIPT)
  • Genomic sequencing services
  • Oncology/infectious-disease genomic tests

Customers

  • Hospitals
  • Government health programs
  • Research institutes

Where it sits in the supply chain

  • Health Care
  • Genomics
  • Sequencing services & diagnostics

What could go right

  • Genetic testing adoption growth
  • International expansion

What could go wrong

  • NIPT price competition/centralized procurement
  • Geopolitical scrutiny of Chinese genomics data

Moat: narrow (scale, brand, installed base). Large sequencing scale and an early, dominant position in China's NIPT market.

Headquarters: Shenzhen, China · Employees: 3,580

Named competitors

BGI Genomics at a glance

Size BGI Genomics (300676.SZ) is a China Health Care company (Biotechnology) with a market value of $2.13B, the 1108th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥34.80 on 18 Nov 2026.

Performance Over six months the shares fell 14.6%, against -4.8% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 0.3% over the last twelve months (peer median +9.4%); the operating margin is -13.6% (peer median -24.1%).

Valuation It trades at 126.7× forward earnings against a peer median of 14.6× (most expensive of 5).

Capital Return on invested capital runs 11.0 points below its cost of capital (9.7% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 95300676.SZ 87
Six months, rebased to 100: BGI Genomics against the median of its 20 peers (local-currency closes).

BGI Genomics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.72BCN¥3.70BCN¥3.86BCN¥4.34BCN¥7.05B
Revenue growth—-4%-11%-38%—
Gross profitCN¥1.60BCN¥1.20BCN¥1.41BCN¥2.02BCN¥3.55B
EBITDAn/aCN¥5.14M-CN¥132MCN¥583MCN¥1.22B
Net income-CN¥545M-CN¥617M-CN¥903MCN¥92.9MCN¥803M
Free cash flow-CN¥223M-CN¥496M-CN¥336M-CN¥587M-CN¥1.03B
Capital expenditureCN¥550MCN¥506MCN¥529MCN¥1.24BCN¥1.27B
Total debtCN¥785MCN¥784MCN¥686MCN¥1.23BCN¥1.25B

Quarterly statements and history in the cockpit →

BGI Genomics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%ALMRPVLAZEALCLDXBEAMPHVS302440RCUS300255MRVIREPLSEPN300676.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. BGI Genomics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×ZEALAUPHVIMIANBCRX300676.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BGI Genomics is the large dot.

BGI Genomics competitors and peer comparison

Head to head with its named competitors (300676.SZ vs ILMN vs NTRA vs 000710.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BGI Genomics 300676.SZ$2.13B-15%0%-14%126.7×n/a
Illumina ILMN$31.8B+48%+6%21%35.2×27.2%
Natera NTRA$42.0B+41%+37%-9%n/an/a
Berry Genomics 000710.SZ$439M-17%-2%-24%n/an/a

How BGI Genomics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BGI Genomics against its 20 peers (data as of 18 Nov 2026)
Measure300676.SZPeer medianRank in peer set
1-month return-17.1%-1.6%4th lowest of 21
6-month return-14.6%-4.8%8th lowest of 20
Distance from 52-week high-46.5%-32.8%6th lowest of 21
Revenue growth (TTM)+0.3%+9.4%8th lowest of 17
Operating margin-13.6%-24.1%6th highest of 15
Forward P/E126.7×14.6×most expensive of 5
ROIC minus cost of capital-11.0 pp-12.2 pp5th highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BGI Genomics 300676.SZChina$2.13B-15%0%-14%126.7×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%7.2×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%n/an/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%n/an/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%38.4×13.4%+44.5%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%n/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%n/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a

Questions

Who are BGI Genomics's main competitors?
Named competitors: Illumina (ILMN), Natera (NTRA), Berry Genomics (000710.SZ). The cockpit's measured peer set (industry) also includes Alamar Biosciences (ALMR), Palvella Therapeutics (PVLA), Zealand Pharma A/S (ZEAL.CO), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), Evopoint Biosciences (688837.SS).
Is BGI Genomics expensive compared with its peers?
On forward p/e it trades at 126.7× against a peer median of 14.6×, most expensive of 5 in its peer set.
How has BGI Genomics stock performed?
Over six months to 18 Nov 2026 the shares returned -14.6% against -4.8% for the median peer; over one year -28.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.